Swedish pharmaceutical company Medivir AB (STO:MVIR) announced on Wednesday that it has received a European patent covering the combination of fostroxacitabine bralpamide (fostrox) and lenvatinib (Lenvima) for treating hepatocellular carcinoma (HCC) and liver metastases.

This patent grants market exclusivity until April 2041, reinforcing Medivir's intellectual property position in liver cancer therapeutics.

The patent approval is part of Medivir's strategy to protect clinically significant combinations involving fostrox in liver cancer treatment. It follows positive final data from the phase 1b/2a study presented at the EASL Liver Cancer Summit and supports the company's ongoing efforts to initiate a phase 2b study in second-line HCC.